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ABSTRACT  
Aim: Our aim was to conduct a systematic review and meta-analysis to determine the risk 
of cardiovascular events and all-cause mortality associated with sulfonylureas versus 
other antihyperglycaemic drugs in patients with type 2 diabetes. 
 
Materials and Methods: A systematic review of Medline, Embase, Cochrane, and 
clinicaltrials.gov was conducted comparing sulfonylurea to placebo or other 
antihyperglycaemic drugs in patients with type 2 diabetes. A cloglog model was 
employed in the Bayesian framework to obtain comparative hazard ratios between 
interventions. For the analysis of observational data, conventional fixed-effect pairwise 
meta-analyses were employed.  
 
Results: The systematic review identified 82 randomized controlled trials (RCTs) and 26 
observational studies. Meta-analyses of RCT data showed an increased risk of all-cause 
mortality and cardiovascular related mortality for sulfonylureas compared to all other 
treatments combined (HR 1·26, 95% CI 1·10-1·44 and HR 1·46, 95% CI 1·21-1·77, 
respectively). The risk of myocardial infarction was significantl  higher for sulfonylureas 
compared to DPP-4 inhibitors and SGLT-2 inhibitors (HR 2·54, 95% CI 1·14-6·57 and 
HR 41·80, 95% CI 1·64-360·4, respectively). The risk of stroke was significantly higher 
for sulfonylureas compared to DPP-4 inhibitors, GLP-1 agonists, TZDs, and insulin.  
 
Conclusion: This meta-analysis shows an association between sulfonylurea therapy and a 
higher risk of major cardiovascular disease-related events compared to other 
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antihyperglycaemic drugs. Results of ongoing RCTs, which should be available in 2018, 
will provide definitive results on the risk of cardiovascular events and all-cause mortality 
associated with sulfonylureas versus other antihyperglycaemic drugs. 
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INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is known to increase the risk of cardiovascular (CV) 
disease, with a 2–5 fold increased risk of life-threatening events such as acute myocardial 
infarction (MI) and stroke.
1,2
 Recent trials have shown that glucose-lowering treatments 
may have different, sometimes divergent, effects on CV risk.
3
 Sulfonylureas (SUs) are 
among the most commonly used treatments for patients with T2DM, yet their long-term 
safety and their effects on CV outcomes remain uncertain and controversial.
4 
The 
possibility that SUs increase CV risk is based on proposed 1) direct effects of SUs on 
myocardium,
5-8
 and 2) indirect effects of SUs on CV function.
9-11
  
 
Adequately designed and prospectively conducted RCTs to evaluate the risk of SUs on 
CV events compared to other commonly prescribed antihyperglycaemic drugs have not 
yet been completed. Several systematic reviews and meta-analyses have compared SUs 
with a variety of antihyperglycaemic drugs. However, findings of these studies are 
inconsistent; this may be due to differences in study selection and statistical techniques 
used to analyze the data.
12-19
  
 
Using advanced meta-analytical techniques, the aim of this study was to assess the risk of 
CV-related outcomes associated with SUs versus other antihyperglycaemic drugs using 
data from RCTs and comparative observational studies. Analyses of survival data were 
performed separately for both RCT evidence and observational evidence to facilitate a 
multi-level inference approach.  
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MATERIALS AND METHODS 
Overview 
We conducted a systematic literature review to identify studies that compared SU 
monotherapy or a SU in combination with another antihyperglycaemic drug against 
placebo/no intervention or other antihyperglycaemic drugs. Data derived from the studies 
identified in the systematic literature review were used to compare the risk of CV events 
associated with the use of SUs and the other selected treatments.  
 
Eligibility criteria 
The eligibility criteria used to select studies in the systematic literature review are 
presented according to the PICOS (population, intervention, control, outcomes, study 
design) convention (Supplementary Table 1). In brief, RCTs and non-randomized 
comparative studies, including prospective or retrospective observational cohort studies 
and case-control studies, conducted among adult patients diagnosed with T2DM who 
were either treatment naïve or had prior exposure to antihyperglycaemic drugs were 
eligible for inclusion. Eligible interventions included SU monotherapy or a SU in 
combination with a biguanide or another antihyperglycaemic drug (i.e. biguanides, 
dipeptidyl peptidase protein-4 [DPP-4] inhibitors, glucagon-like peptide-1 [GLP-1] 
agonists, sodium-glucose linked transporter-2 [SGLT-2] inhibitors, thiazolidinediones 
[TZDs], insulin). Eligible comparators included placebo/no intervention or other 
antihyperglycaemic drugs. Outcomes of interest included all-cause mortality, CV-related 
mortality, acute MI, and stroke.   
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Literature search 
A systematic search of the peer-reviewed literature was conducted in Medline, Embase, 
and Cochrane Register of Controlled Trials from inception to December 2014 
(Supplementary Table 2 presents the search strategy used). Additionally, 
clinicaltrials.gov was searched to identify potentially eligible RCTs with results that had 
not yet been published in a peer-reviewed journal.  
 
Two investigators independently identified relevant abstracts and full-text publications 
based on the eligibility criteria. If any discrepancies occurred between the studies 
selected by the two investigators, a third investigator provided arbitration. For all the 
articles that were not published in English language, a separate search was conducted 
using the author names to see if a relevant publication in English exists. If not, non-
English publications were discarded.  
 
Data extraction 
Two reviewers working independently extracted data on study characteristics, 
interventions, patient characteristics at baseline, and outcomes for the study populations 
of interest for the eligible studies. If discrepancies occurred between the data extracted by 
the two reviewers, these differences were reconciled by involving a third reviewer. In the 
event that the third reviewer could not resolve a disagreement, the authors of the 
publication were contacted for clarification.  
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Data on all outcomes were extracted as intention-to-treat analyses, where all dropouts 
were assumed to be treatment failures, wherever trial reporting allowed this. For studies 
that reported “per-protocol” results only, these were extracted and used in the analyses. 
For observational studies, we focused on extracting adjusted estimates representing 
comparative effects through hazard ratios, odds ratios, or relative risks as intention-to-
treat and per-protocol issues were not relevant. 
 
Study quality 
For included RCTs, we assessed the validity of individual trials using the Risk of Bias 
instrument, endorsed by the Cochrane Collaboration.
20
 This instrument is used to 
evaluate six key domains: sequence generation; allocation concealment; blinding of 
participants, personnel, and outcome assessors; incomplete outcome data; selective 
outcome reporting; and other sources of bias. 
 
For observational studies, we used the Newcastle-Ottawa scale. With this scale, each 
study is judged on eight items, categorized into three groups: the selection of the study 
groups; the comparability of the groups; and the ascertainment of either the exposure or 
outcome of interest for case-control or cohort studies respectively. Stars awarded for each 
quality item serve as a quick visual assessment. 
 
The same two reviewers extracting data conducted the quality assessment. If 
disagreements between the reviewers occurred, we resolved these by including a third 
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reviewer, and if necessary, contacting the authors of the publication for clarification. No 
studies were excluded on the basis of quality. 
 
Evidence synthesis 
Treatments were grouped according to drug class. First- and second-generation SUs were 
treated as one group. Other drug classes included biguanides, DPP-4 inhibitors, GLP-1 
agonists, SGLT-2 inhibitors, TZDs, and insulins. When biguanides were used as 
background therapy, the intervention therapy was analyzed as a monotherapy.  
 
For all four outcomes (all-cause mortality, CV-related mortality, acute MI, and stroke), 
meta-analysis was employed to establish comparative results between SU versus other 
drug classes. The hazard ratio was employed as a primary effect measure (i.e. primary 
analysis). Analyses were performed separately for RCT evidence and observational 
evidence to facilitate a multi-level inference approach. 
 
For the primary analysis of RCT data, a Bayesian hierarchical approach was employed in 
the framework of indirect treatment comparisons. The choice whether to use a fixed- or 
random-effects model was determined by comparing the values of the deviance 
information criterion for each model as well as assessing the heterogeneity variance 
provided in the random-effects model. Since RCT data were only available as binary 
data, but at differing time points, and since the effect measure of interest was the hazard 
ratio, a binomial model with a cloglog link function and a time offset (cloglog model) 
was employed in the Bayesian framework to obtain comparative hazard ratios between 
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interventions.
21
 For the primary analysis of observational data, conventional fixed-effect 
pairwise meta-analyses were employed to pool adjusted hazard ratios for each pair-wise 
treatment comparison.  
 
Since the outcomes typically only occurred once, we assumed that adjusted relative risks 
from observational studies could be considered similar to adjusted hazard ratios, and thus 
pooled the two where relevant. From the cloglog model of RCT data, we further 
estimated the survival functions for each of the interventions of interest. From these 
survival functions, we calculated the absolute difference in risk of each outcome between 
SU and each of the other interventions.  Since observational studies represent pragmatic 
clinical practice, and clinical trials are controlled settings, we included observational 
studies to perform an external validity check for the RCT evidence. We acknowledge 
that, our study is not hypothesis testing, however, we believe that with the external 
validity check for the RCTs, this systematic review work will be placed between 
exploratory and hypothesis testing.  We additionally calculated the same absolute 
differences in risk based on the observational data, using the estimated survival function 
for SU and the pooled (observational) hazard ratios to produce survival functions for the 
other interventions.  
 
We produced two types of forest plots to graphically display the results. The first 
compared the study specific estimates provided in each study and the second compared 
the relative efficacies between treatments as estimated in the analysis. In traditional meta-
analysis, forest plots are used to present the results from individual studies and the 
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synthesized result from the analysis, providing a visual assessment of the statistical 
heterogeneity. Statistical heterogeneity is caused by differences in factors that influence 
the outcome or the intervention, such as prognostic factors. As explained above, our 
analyses account for an important effect modifier, namely time. Longer follow-up periods 
lead to higher probabilities of an event occurring. 
 
Since prescription of rosiglitazone had been limited or suspended in many countries due 
to CV safety concerns 
22, 23
 , a sensitivity analysis was conducted excluding this treatment 
from the TZD class. 
 
All Bayesian analyses were performed in WinBUGS v3.1.4, and all conventional meta-
analyses and figures were performed and produced using R v3.1.2. 
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RESULTS 
Included studies 
The systematic literature review yielded 14,841 abstracts for screening. Subsequently 830 
full-text articles were reviewed, of which 722 were excluded: 64 due to an ineligible 
population, 93 due to an ineligible intervention, 36 due to an ineligible comparison, 393 
due to lack of outcomes of interest, 126 due to an ineligible study design, and 10 for other 
(e.g. study not in English language). Of these, 108 studies were included (82 RCTs and 
26 observational studies). The flow of study selection is presented in Supplementary 
Figure 1, and the summary of baseline characteristics and quality of included studies is 
presented in Supplementary Table 3 – Supplementary Table 8.  
 
All-cause mortality 
The results of the analysis of all-cause mortality for the RCT and observational evidence 
are detailed in Table 1 and Figure 1.A. Additionally, Supplementary Figure 2 presents the 
forest plot for showing individual study results. When considering RCT evidence, the 
results indicate an increased risk of all-cause mortality for SUs in comparison to all other 
active treatments (HR 1·26, 95% CI 1·10-1·44). Four of these comparisons were 
statistically significant: SUs versus biguanides (HR 1·37, 95% CI 1·03-1·84), DPP-4 
inhibitors (HR 2·03, 95% CI 1·22-3.58), TZDs (HR 1·54, 95% CI 1·14-2·10), and 
insulins (HR 1·21, 95% CI 1·01-1·45). When compared to no active treatment, SUs 
demonstrated an increase in risk, however this was not statistically significant.  
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Where observational evidence was available, results trended in the same direction as the 
RCT evidence, with the exception of SUs versus insulins, with a HR 0.82 (0.77-0.89). 
Each comparison using observational evidence was statistically significant.  
 
Cardiovascular-related mortality 
The results of the analyses of the risk of CV-related mortality are presented in Table 1 
and Figure 1.B. In addition, Supplementary Figure 3 provides the forest plot showing 
individual study results. Analyses of RCT evidence indicated that there is an increased 
risk of CV related mortality for SUs in comparison to all other active treatments (HR 
1·46, 95% CI 1·21-1·77). These results were statistically significant for SUs versus DPP-
4 inhibitors (HR 4·42, 95% CI 1·92-13·0), GLP-1 agonists (HR 45·4, 95% CI 2·07-
362·8), SGLT-2 inhibitors (HR 42·6, 95% CI 1·71-359·1), TZDs (HR 3·05, 95% CI 
1·79-5·54), and insulins (HR 1.30, 95% CI 1·02-1·66). When compared to no active 
treatment, SUs demonstrated an increase in risk, however this was not statistically 
significant.  
 
Observational data were only available for the SU versus no treatment and insulin 
comparisons. Similar to the RCT evidence, SUs tended to have a greater risk of CV-
related mortality with the observational evidence, however this was not statistically 
significant. When considering SUs versus insulins with observational evidence, the risk 
of CV-related mortality was in the opposite direction of the RCT data, although this 
estimate was not statistically significant.  
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Acute myocardial infarction 
The results of the analyses of the risk of acute MI are provided in Table 1 and Figure 1.C. 
Additionally, Supplementary Figure 4 presents the forest plot showing the individual 
study results. The analyses of RCT evidence demonstrated that SUs increased the risk of 
acute MI in comparison to all other active treatments, with the exception of insulins. 
These results were statistically significant for SUs versus DPP-4 inhibitors (HR 2·54, 
95% CI 1·14-6·57) and SGLT-2 inhibitors (HR 41·8, 95% CI 1·64-360·4). Although 
results indicate a decrease in the risk of acute MI for SUs compared to no active 
treatment, this comparison was not statistically significant.  
 
Observational data were also available for the comparison of SUs versus TZDs. The 
increased risk of acute MI with the use of SUs compared to TZDs was statistically 
significant when considering observational evidence.  
 
Stroke 
The results of the analyses of the risk of stroke are provided in Table 1 and Figure 1.D. In 
addition, Supplementary Figure 5 presents the forest plot showing the individual study 
results.  The analysis of RCT evidence indicated that SUs increased the risk of stroke 
relative to all other active treatments. These results were statistically significant for the 
comparisons of SUs versus DPP-4 inhibitors (HR 9·40, 95% CI 3·27-41·9), GLP-1 
inhibitors (HR 45·4, 95% CI 1·99-362·7), TZDs (HR 1·75, 95% CI 1·20-2·69), and 
insulins (HR 1·46, 95% CI 1·01-2·14). When SUs were compared to no active treatment, 
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there was an increase in risk, however this estimate was not statistically significant. No 
observational data were available for this outcome. 
 
Sensitivity analysis 
When excluding rosiglitazone in the comparison of SUs versus TZDs, the risk of all-
cause mortality (HR 3·58, 95% CI 1·87-7·87), CV-related mortality (HR 3·62, 95% CI 
1·88-7·96), acute MI (HR 1·44, 95% CI 0·87-2·50), and stroke (HR 2·07, 95% CI 1·12-
4·19) increased with the RCT evidence base. However, when removing rosiglitazone in 
the analyses of the observational evidence base, the results were comparable.   
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DISCUSSION 
This study is the most comprehensive review of RCTs and observational studies to 
compare CV-related outcomes and all-cause mortality among patients with T2DM treated 
with a SU versus other antihyperglycaemic agents, including insulin and the newer drugs 
such as SGLT-2 inhibitors. Results for the RCT pooled hazard ratios indicate that 
treatment with a SU was associated with a significantly higher risk of all-cause mortality 
and CV-related mortality when compared to all other treatments. All-cause mortality and 
CV-related mortality had the greatest number of statistically significant results and the 
analysis of observational studies generally supported the results from RCTs. The 
associations between DPP-4 inhibitors, GLP-1 agonists, and SGLT-2 inhibitors and SU 
for CV-related mortality, as well as SGLT-2 inhibitors and SU for acute myocardial 
infarction and DPP-4 inhibitors and GLP-1 agonists and SU for stoke, should be 
interpreted with cautions due to wide confidence intervals. 
 
There were two major discrepancies between the observational and RCT analyses. First, 
the comparison of SU and insulin for the outcome of CV-related mortality; RCT results 
showed a significant increase in risk for SUs, while observational results showed a 
decrease in risk. The observational data were, however, sparse (only two trials available) 
which may explain the lack of statistical significance. The second was the comparison of 
SU and insulin for the outcome of all-cause mortality; the RCT results showed a 
significant increase in risk while the observational evidence suggested a significant 
decrease. However, the observational data exhibited significant heterogeneity as 
identified with the Cochrane-Q (p-value < 0.001), which may explain this discrepancy. 
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The differences between RCTs and observational studies, in the direction of effect for all 
cause and cardiovascular mortality, might also be due to the differences in the insulin 
administration in the RCTs and observational studies, which reflect the clinical practice 
settings. 
 
Several systematic reviews have addressed similar topics concerning SU therapy.
9,12-
15,18,24,25,26
 However, these studies had important methodological limitations, in particular 
grouping treatments with diverse safety profiles, imprecise study inclusion criteria, non-
systematic searches, and important analytical limitations. Four of the studies reported 
similar results to ours for all-cause mortality and CV-related mortality.
12,15,18,25
 Two of 
these studies only included subsets of SUs.
9,24
 Two of these reviews were associated with 
methodological limitations, such as incorrect inclusions, inconsistent reporting, and lack 
of a rigorous search strategy.
13,14
 Furthermore, one recent review assessed CV outcomes, 
however this meta-analysis only included SUs and aimed to report on differences with in 
this treatment class.
26
 The most recent meta-analysis on this topic was presented by 
Rados et al at the American Diabetes Association 2015 Scientific Sessions.
19
 These 
investigators generally concluded that SUs are not associated with increased mortality, 
with the exception of glipizide, which increased the risk for total and CV-related 
mortality.  
 
SU-mediated inhibition of ischaemic preconditioning and hypoglycaemia-related 
arrhythmogenesis are the principal mechanisms cited to support the biological plausibility 
of a harmful link between SUs and CV disease.  However, very few RCTs with SUs have 
Page 17 of 29
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 18
included CV endpoints and the trials to date have been relatively small and of short 
duration. CAROLINA (NCT01243424), an ongoing multicentre, randomized, double 
blind, active controlled trial, aims to assess increased cardiovascular risk of linagliptin 
compared to glimepiride, in addition to standard of care.
27
 Another, multicentre, 
randomized, double blind, active controlled trial, is the TOSCA IT trial (NCT00700856). 
This ongoing trial aims to assess the cardiovascular safety of pioglitazone compared to a 
sulphonylurea in type 2 diabetes patients who are not controlled by metformin 
monotherapy.
28
 These two trials will hopefully be able provide a definitive answer to the 
question about the CV risk of sulphonylureas when compared directly to an active 
comparator, a DPP-4 inhibitor or a TZD.  
 
Furthermore, the large studies that have been performed in patients with type 2 diabetes 
treated with SUs, e.g. UKPDS,
29
 and ADVANCE,
30
 are of limited value since these trials 
evaluated the effects of glycaemic control rather than the effects of specific 
antihyperglycaemic agents.  Thus, in the absence of conclusive RCT data, the current 
meta-analysis offers the most comprehensive overview of SU trials using Bayesian 
techniques to quantify relative differences in major CV outcomes and all-cause mortality 
versus placebo (or no treatment) and other classes of antihyperglycaemic drugs, including 
insulin therapy and the SGLT-2 inhibitors. Our analysis includes RCTs and observational 
studies, and overcomes many of the limitations of earlier analyses. 
 
The current analysis also has some limitations. First, the number of analyses conducted 
may have introduced multiplicity, i.e. a type one error (false positive) may have occurred 
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in a comparison estimate. Second, the minimal amount of data in some analyses did not 
allow for robust effect estimates. For instance, low event counts in some comparisons 
resulted in wide confidence intervals and potentially misleading large risk differences. 
Third, our analyses focused on class effects to ensure sufficient sample sizes to detect 
differences; however, it should be recognized that individual SU treatments may differ in 
terms of mortality risk.
26
 Fourth, meta-analyses of randomized trials is not designed a 
priori to test a hypothesis and rather should only be considered as hypothesis generating, 
however, inclusion of bservational studies to validate the RCTs, will place this work 
between exploratory and hypothesis testing. Finally, there are inherent flaws in meta-
analyses, which rely on high-quality study data. The current study used a rigorous search 
and extraction method to ensure high quality evidence was integrated appropriately. Risk 
of bias assessments were performed for both RCTs and observational studies to 
summarize study quality. 
 
Our meta-analysis findings showed an association between sulfonylurea therapy and a 
higher risk of cardiovascular-related events compared to other antihyperglycaemic drugs. 
This risk observed in RCTs was confirmed with data from the observational studies. The 
CAROLINA and TOSCA IT trials should have results in 2018 and will provide more 
definitive answers regarding whether the effect of sulfonylureas on cardiovascular risk 
relative to other antihyperglycaemic drugs. 
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Figure Titles and Legends 
 
Figure 1.A: Forest plot presenting hazard ratio estimates of all-cause mortality for 
sulfonylureas versus other antihyperglycemic drugs 
 
Figure 1.B: Forest plot presenting hazard ratio estimates of cardiovascular-related 
mortality for sulfonylureas versus other antihyperglycemic drugs 
 
Figure 1.C: Forest plot presenting hazard ratio estimates of acute myocardial infarction 
for sulfonylureas versus other antihyperglycemic drugs 
 
Figure 1.D: Forest plot presenting hazard ratio estimates of stroke for sulfonylureas 
versus other antihyperglycemic drugs 
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Table 1: Difference between sulfonylureas and other treatments for cardiovascular-related 
and mortality outcomes 
 RCT Observational 
Sulfonylurea vs HR (95% CI) HR (95% CI) I
2
 % (95% CI) 
All-cause mortality 
No active treatment/ 
placebo 
1.07 (0.90-1.28) 1.13 (1.07-1.19) 63.5 (14.2-79.3)
a
 
Biguanide 1.37 (1.03-1.84) 1.57 (1.48-1.66) 0.00 (0.00-64.1) 
DPP-4 inhibitor 2.03 (1.22-3.58) 1.58 (1.36-1.83) 0.00 (0.00-72.9) 
GLP-1 agonist 1.85 (0.80-5.19) - - 
SGLT-2 inhibitor - - - 
Thiazolidinedione 1.54 (1.14-2.10) 1.50 (1.32-1.71) 96.6 (93.9-97.8)
b
 
Insulin 1.21 (1.01-1.45) 0.82 (0.77-0.89) 92.4 (86.7-95.0)
b
 
Combined 1.26 (1.10-1.44) 1.22 (1.18-1.26) 92.4 (90.6-93.7)
b
 
Cardiovascular-related mortality 
No active treatment/ 
placebo 
1.25 (0.98-1.62) 1.16 (0.93-1.44) 73.9 (0.00-88.6)
a
 
Biguanide 1.38 (0.90-2.16) - - 
DPP-4 inhibitor 4.42 (1.92-13.0) - - 
GLP-1 agonist 45.4 (2.07-362.8) - - 
SGLT-2 inhibitor 42.6 (1.71-359.1) - - 
Thiazolidinedione 3.05 (1.79-5.54) - - 
Insulin 1.30 (1.02-1.66) 0.80 (0.52-1.24) - 
Combined 1.46 (1.21-1.77) 1.01 (0.89-1.14) 80.8 (58.6-88.6)
b
 
Acute myocardial infarction 
No active treatment/ 
placebo 
0.86 (0.70-1.06) - - 
Biguanide 1.21 (0.78-1.99) - - 
DPP-4 inhibitor 2.54 (1.14-6.57) - - 
GLP-1 agonist 1.49 (0.45-5.41) - - 
SGLT-2 inhibitor 41.8 (1.64-360.4) - - 
Thiazolidinedione 1.13 (0.83-1.59) 1.41 (1.23-1.62) 36.7 (0.00-78.3) 
Insulin 0.96 (0.78-1.18) - - 
Combined 0.92 (0.78-1.08) 1.34 (1.25-1.44) 16.5 (0.00-67.1) 
Stroke 
No active treatment/ 
placebo 
1.26 (0.88-1.81) - - 
Biguanide 1.40 (0.92-2.22) - - 
DPP-4 inhibitor 9.40 (3.27-41.9) - - 
GLP-1 agonist 45.4 (1.99-362.7) - - 
SGLT-2 inhibitor - - - 
Thiazolidinedione 1.75 (1.20-2.69) - - 
Insulin 1.46 (1.01-2.14) - - 
Combined 1.09 (0.86-1.39) - - 
Note: Bold text indicates statistical significance (95% confidence interval does not include 1.00); Pooled hazard 
ratios for RCTs were obtained by cloglog analysis; Random effect estimates were equivalent to fixed effect 
estimates for observational studies; Data reported is or the > 1 year time point; – not applicable due to lack of trial 
data; 
a
 - p-value < 0.01; 
b
 - p-value < 0.001  
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Figure 1.A: Forest plot presenting hazard ratio estimates of all-cause mortality for 
sulfonylureas versus other antihyperglycemic drugs 
Note: No data were available for the SGLT-2 inhibitors vs. sulfonylureas for all-cause mortality.  
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Figure 1.B: Forest plot presenting hazard ratio estimates of cardiovascular-related 
mortality for sulfonylureas versus other antihyperglycemic drugs 
 
Note: The hazard ratios for DPP-4 inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists versus sulfonylureas should be 
interpreted with caution given the wide confidence intervals.  
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Figure 1.C: Forest plot presenting hazard ratio estimates of acute myocardial 
infarction for sulfonylureas versus other antihyperglycemic drugs 
 
Note: The hazard ratio for SGLT-2 inhibitors versus sulfonylureas should be interpreted with caution given the wide confidence 
interval.  
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Figure 1.D: Forest plot presenting hazard ratio estimates of stroke for sulfonylureas 
versus other antihyperglycemic drugs 
Note: No data were available for SGLT-2 inhibitors versus sulfonylureas for stroke. The hazard ratios for the DPP-4 inhibitors and 
GLP-1 receptor agonists versus sulfonylureas should be interpreted with caution given the wide confidence intervals. 
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